Q3 2023 13F Holders as of 9/30/2023
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
70.9M
-
Number of holders
-
81
-
Total 13F shares, excl. options
-
34.6M
-
Shares change
-
+510K
-
Total reported value, excl. options
-
$64.3M
-
Value change
-
+$59K
-
Put/Call ratio
-
1.83
-
Number of buys
-
37
-
Number of sells
-
-51
-
Price
-
$1.86
Significant Holders of C4 Therapeutics, Inc. - Common Stock (CCCC) as of Q3 2023
105 filings reported holding CCCC - C4 Therapeutics, Inc. - Common Stock as of Q3 2023.
C4 Therapeutics, Inc. - Common Stock (CCCC) has 81 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 34.6M shares
of 70.9M outstanding shares and own 48.78% of the company stock.
Largest 10 shareholders include WASATCH ADVISORS LP (6.25M shares), Soleus Capital Management, L.P. (2.69M shares), ArrowMark Colorado Holdings LLC (2.38M shares), PRICE T ROWE ASSOCIATES INC /MD/ (2.19M shares), BlackRock Inc. (2.1M shares), Aquilo Capital Management, LLC (1.99M shares), VANGUARD GROUP INC (1.92M shares), Bain Capital Life Sciences Investors, LLC (1.64M shares), TCG Crossover Management, LLC (1.28M shares), and MILLENNIUM MANAGEMENT LLC (1.17M shares).
This table shows the top 81 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.